Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 14,134 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Dry Eye Disease
Interventions: GRF312 5%, Placebo Comparator; Drug · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Glendale, California • Grove, California • Newport Beach, California + 7 more

Conditions: Hidradenitis Suppurativa
Interventions: infliximab, Placebo Comparator; Drug
Lead sponsor: Florida Academic Dermatology Centers; Other
Eligibility: 16 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain, Osteoarthritis, Knee
Interventions: Transdermal Ketoprofen Patch with CHADD, Placebo transdermal patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 5
States / cities: Buena Park, California • Washington D.C., District of Columbia • Daytona Beach, Florida + 2 more

Conditions: AML, MDS
Interventions: SOC + TSC-101, Control, SOC + TSC-100; Drug · Other
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 21
States / cities: Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more

Conditions: Hypercholesterolemia
Interventions: AZD8233; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Glendale, California

Conditions: Skin Diseases, Infectious, Skin Diseases, Bacterial
Interventions: TR-701 200 mg, TR-701 300 mg, TR-701 400 mg; Drug
Lead sponsor: Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 12
States / cities: Dothan, Alabama • Chula Vista, California • Long Beach, California + 9 more

Conditions: Hypertension
Interventions: Placebo, ALN-AGT01; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 54
States / cities: Birmingham, Alabama • Tempe, Arizona • Beverly Hills, California + 44 more

Conditions: Healthy Volunteers, Pharmacokinetics of ASP015K
Interventions: ASP015K, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Iron Deficiency Anemia
Interventions: Ferric carboxymaltose, Ferrous Sulfate; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 16
States / cities: Little Rock, Arkansas • Doral, Florida • Miami, Florida + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Etanercept, CHS-0214; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 37
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 32 more

Conditions: Schizophrenia
Interventions: Elpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 35
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Healthy Volunteers
Interventions: Bendavia 10mg, Bendavia 50mg, Placebo; Drug
Lead sponsor: Mighty Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Psoriatic Arthritis
Interventions: Placebo, Bimekizumab; Other · Drug
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: San Diego, California • Aventura, Florida • Hagerstown, Maryland + 10 more

Conditions: Bipolar Depression
Interventions: Deep TMS Treatment, Sham Treatment; Device
Lead sponsor: Brainsway; Industry
Eligibility: 22 Years to 68 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 9
States / cities: Juno Beach, Florida • Palm Beach, Florida • Royal Palm Beach, Florida + 6 more

Conditions: Hyperkalemia
Interventions: Zirconium silicate (acute phase), Zirconium silicate (subacute phase), Placebo (acute phase), Placebo ( subacute phase); Drug
Lead sponsor: ZS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 42
States / cities: Anniston, Alabama • Huntsville, Alabama • Glendale, Arizona + 37 more

Conditions: Hidradenitis Suppurativa (HS)
Interventions: Tibulizumab Dose A, Tibulizumab Dose B, Placebo; Biological · Other
Lead sponsor: Zura Bio Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 34
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 30 more

Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Interventions: Vutrisiran, Sterile Normal Saline (0.9% NaCl); Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 17
States / cities: La Mesa, California • Los Angeles, California • Stanford, California + 13 more

Conditions: Cardiovascular Disease
Interventions: SLCO1B1 Genotype; Genetic
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 75 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Growth Hormone Deficiency (GHD)
Interventions: LUM-201, Matched Placebo (Capsules); Drug · Other
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Madera, California • Orange, California + 28 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: AZD6793, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 86
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 70 more

Conditions: Alzheimer's Disease
Interventions: Placebo, octagam 10%; Drug · Biological
Lead sponsor: Octapharma; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hoboken, New Jersey

Conditions: Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy
Interventions: Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo; Drug
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more

Conditions: Safety Issues
Interventions: GB002, Generic Dry Powder Inhaler, Placebo; Drug · Device
Lead sponsor: GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Keratoconus
Interventions: riboflavin solution, placebo solution, KXL System; Drug · Device
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 12 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 10
States / cities: Irvine, California • Miami, Florida • Atlanta, Georgia + 7 more

Search by objective public record fields.

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8233 in Healthy Male Subjects With Increased Elevated LDL-C Levels.

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects

Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

Safety and Efficacy Study of Deep Transcranial Magnetic Stimulation in Bipolar Depression

Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Integrating Pharmacogenetics In Clinical Care

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus